## Empagliflozin for COVID-19

1	
2	
3	Empagliflozin in patients admitted to hospital with
4	COVID-19 (RECOVERY): a randomised, controlled,
5	open-label, platform trial
6	
7	Running title: Empagliflozin for COVID-19
8	
9	<b>RECOVERY Collaborative Group*</b>
10	
11	
12	*The writing committee and trial steering committee are listed at the end of this
13	manuscript and a complete list of collaborators in the Randomised Evaluation of
14	COVID-19 Therapy (RECOVERY) trial is provided in the Supplementary Appendix.
15	
16	Correspondence to: Prof Peter W Horby and Prof Martin J Landray, RECOVERY Central
17	Coordinating Office, Richard Doll Building, Old Road Campus, Roosevelt Drive, Oxford OX3
18	7LF, United Kingdom.
19	Email: recoverytrial@ndph.ox.ac.uk
20	
21	Word count:
22	Abstract – 255 words
23	Main text – 2846 words
24	References – 25
25	Tables & Figures – 2+3
26 27	
- 1	

#### Empagliflozin for COVID-19

#### 28 SUMMARY

Background: Empagliflozin has been proposed as a treatment for COVID-19 on the
 basis of its anti-inflammatory, metabolic and haemodynamic effects.

Methods: In this randomised, controlled, open-label trial, several possible treatments are 31 32 compared with usual care in patients hospitalised with COVID-19. Eligible and consenting 33 adults were randomly allocated in a 1:1 ratio to either usual standard of care alone or 34 usual standard of care plus empagliflozin 10mg once daily for 28 days or until discharge 35 using web-based simple (unstratified) randomisation with allocation concealment. The 36 primary outcome was 28-day mortality. On 3 March the independent data monitoring 37 committee recommended that the investigators review the data and recruitment was 38 consequently stopped on 7 March. The trial is registered with ISRCTN (50189673) and 39 clinicaltrials.gov (NCT04381936).

40 Findings: Between 8 July 2021 and 6 March 2023, 4271 patients were randomly 41 allocated to receive either empagliflozin (2113 patients) or usual care alone (2158 42 patients). Overall, 289 (14%) patients allocated to empagliflozin and 307 (14%) patients 43 allocated to usual care died within 28 days (rate ratio 0.96; 95% confidence interval [CI] 44 0.82-1.13: p=0.64). There was no evidence of significant differences in duration of 45 hospitalisation (median 8 days vs. 8 days) or the proportion of patients discharged from hospital alive within 28 days (79% vs. 78%; rate ratio 1.03; 95% CI 0.96-1.10; p=0.44). 46 47 Among those not on invasive mechanical ventilation at baseline, there was no evidence 48 of a significant difference in the proportion meeting the composite endpoint of invasive 49 mechanical ventilation or death (16% vs. 17%; risk ratio 0.95; 95% CI 0.84-1.08; p=0.44).

# Empagliflozin for COVID-19

- 50 Interpretation: In adults hospitalised with COVID-19, empagliflozin was not associated
- 51 with reductions in 28-day mortality, duration of hospital stay, or risk of progressing to
- 52 invasive mechanical ventilation or death.
- 53 **Funding:** UK Research and Innovation (Medical Research Council) and National Institute
- of Health Research (Grant ref: MC\_PC\_19056), and Wellcome Trust (Grant Ref:
- 55 222406/Z/20/Z).
- 56 Trial registration: ClinicalTrials.gov NCT04381936
- 57 https://clinicaltrials.gov/ct2/show/NCT04381936
- 58 ISRCTN50189673 http://www.isrctn.com/ISRCTN50189673
- 59 Keywords: COVID-19, empagliflozin, clinical trial.

#### Empagliflozin for COVID-19

#### 61 **INTRODUCTION**

Patients with cardiometabolic diseases (such as heart failure, diabetes and chronic kidney disease) are at increased risk of hospitalization and death from COVID-19. Sodium glucose co-transporter 2 inhibitors (SGLT2i) have been shown to reduce cardiovascular and kidney events in patients with cardiometabolic diseases.<sup>1</sup> The precise mechanisms of such benefit are not known, but SGLT2i appear to favourably modify some pathways that are dysregulated in acute illnesses like COVID-19.

68 Inflammation is a key feature of severe COVID-19. Markedly raised levels of inflammatory markers such as C-reactive protein, ferritin, interleukin-6 (IL-6) and other cytokines are 69 observed in severe cases and are associated with poor outcomes.<sup>2,3</sup> Corticosteroids, IL-70 71 6 inhibitors and Janus kinase (JAK) inhibitors have been shown to reduce mortality in patients with severe COVID-19.4-6 Together these results show that inflammation is 72 73 modifiable and anti-inflammatory therapy can improve clinical outcomes. SGLT2i can reduce inflammation,<sup>7,8</sup> including via attenuation of the nucleotide binding domain (NOD)-74 75 like pyrin domain 3 (NLRP3) inflammasome, which correlates with disease severity in COVID-19.9,10 A meta-analysis of 26 trials in patients with type 2 diabetes mellitus showed 76 77 a reduced risk of pneumonia and septic shock among patients allocated SGLT2i.<sup>11</sup> In 78 addition, SGLT2i inhibit glycolysis and stimulate lipolysis which may create a less favourable energetic environment for viruses like COVID-19,<sup>12-14</sup> and improve endothelial 79 function.<sup>15</sup> 80

The DARE-19 trial compared dapagliflozin 10mg once daily with placebo in 1250 patients
hospitalised with COVID-19 who had at least one cardiometabolic risk factor but were not

#### Empagliflozin for COVID-19

83 critically ill.<sup>16</sup> The primary outcome of new or worsened organ dysfunction or death 84 occurred in 70 (11%) of the dapaglifozin group versus 86 (14%) in the placebo group (hazard ratio [HR] 0.80, 95% CI 0.58-1.10). The dual primary outcome of improvement in 85 86 clinical status by day 30 was also not significantly affected (win ratio 1.09, 95% CI 0.97-1.22). Dapagliflozin was well-tolerated and appeared safe (with fewer serious adverse 87 88 events reported in the dapaglifozin group compared to placebo). Here we report the 89 results of a large randomised controlled trial of empagliflozin in patients hospitalised with 90 COVID-19.

#### 91 METHODS

#### 92 Study design and participants

93 The Randomised Evaluation of COVID-19 therapy (RECOVERY) trial is an investigator-94 initiated, individually randomised, controlled, open-label, adaptive platform trial to 95 evaluate the effects of potential treatments in patients hospitalised with COVID-19. 96 Details of the trial design and results for other possible treatments (dexamethasone, 97 hydroxychloroquine, lopinavir-ritonavir, azithromycin, tocilizumab, convalescent plasma, 98 colchicine, aspirin, casirivimab plus imdevimab, baricitinib, and high-dose corticosteroids in hypoxic patients not requiring ventilatory support) have been published previously.<sup>6,17-</sup> 99 100 <sup>26</sup> The trial is underway at hospital organisations in the United Kingdom supported by the 101 National Institute for Health and Care Research Clinical Research Network, as well as in 102 South and Southeast Asia and Africa. Of these, 118 hospitals in the UK, 5 in Nepal, 4 in 103 Indonesia, 2 in Vietnam, 4 in South Africa, 1 in Ghana and 5 in India enrolled participants in the evaluation of empagliflozin (appendix pp 2-31). The trial is coordinated by the 104

#### Empagliflozin for COVID-19

Nuffield Department of Population Health at University of Oxford (Oxford, UK), the trial sponsor. The trial is conducted in accordance with the principles of the International Conference on Harmonisation–Good Clinical Practice guidelines and approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and the Cambridge East Research Ethics Committee (ref: 20/EE/0101). The protocol, statistical analysis plan, and additional information are available on the study website www.recoverytrial.net.

Patients admitted to hospital were eligible for the study if they had clinically suspected or 111 112 laboratory confirmed SARS-CoV-2 infection and no medical history that might, in the 113 opinion of the attending clinician, put the patient at significant risk if they were to 114 participate in the trial. Children (age <18 years) and pregnant women were not eligible for 115 randomisation due to limited data on use of empagliflozin in these groups such that it was 116 not possible to make an evidence-based benefit-risk assessment. Patients with type 1 117 diabetes mellitus (or post-pancreatectomy diabetes), a history of ketoacidosis or type 2 118 diabetes mellitus with ketosis at the time of recruitment were ineligible for the comparison 119 of empagliflozin vs. usual care (further details in appendix pp 32-33). Written informed 120 consent was obtained from all patients, or a legal representative if patients were too 121 unwell or unable to provide consent.

#### 122 Randomisation and masking

Baseline data were collected using a web-based case report form that included demographics, level of respiratory support, major comorbidities, suitability of the study treatment for a particular patient, SARS-CoV-2 vaccination status, and treatment availability at the study site (appendix pp 43-45). For some patients, empagliflozin was

#### Empagliflozin for COVID-19

127 unavailable at the hospital at the time of enrolment or was considered by the managing 128 physician to be either definitely indicated or definitely contraindicated. These patients 129 were excluded from the randomised comparison between empagliflozin and usual care. 130 Eligible and consenting adult patients were assigned in a 1:1 ratio to either usual standard 131 of care or usual standard of care plus empagliflozin using web-based simple (unstratified) 132 randomisation with allocation concealed until after randomisation (appendix pp 41-43). 133 Patients allocated to empagliflozin were to receive 10mg orally daily for 28 days in total 134 or until discharge, whichever occurred earlier. Investigators were instructed how to 135 identify and manage ketosis that may develop during treatment with empagliflozin 136 (appendix p 32-33).

As a platform trial, and in a factorial design, patients could be simultaneously randomised to other treatment groups: i) baricitinib versus usual care, ii) higher-dose corticosteroids versus usual care, iii) sotrovimab versus usual care, iv) molnupiravir versus usual care, and v) nirmatrelvir-ritonavir versus usual care (appendix pp 41-42). Participants and local study staff were not masked to the allocated treatment. Other than members of the Data Monitoring Committee, all individuals involved in the trial were masked to aggregated outcome data while recruitment and 28-day follow-up were ongoing.

144

#### 145 **Procedures**

A single online follow-up form was completed when participants were discharged, had
died or at 28 days after randomisation, whichever occurred earliest (appendix pp 47-55).
Information was recorded on adherence to allocated study treatment, receipt of other

#### Empagliflozin for COVID-19

149 COVID-19 treatments, duration of admission, receipt of respiratory or renal support, and 150 vital status (including cause of death). In addition, in the UK, routine healthcare and 151 registry data were obtained including information on vital status (with date and cause of 152 death), discharge from hospital, receipt of respiratory support, or renal replacement 153 therapy. For sites outside the UK a further case report form (appendix pp 56-57) collected 154 vital status at day 28 (if not already reported on follow-up form).

#### 155 **Outcomes**

156 Outcomes were assessed at 28 days after randomisation, with further analyses specified 157 at 6 months. The primary outcome was all-cause mortality at 28 days. Secondary 158 outcomes were time to discharge from hospital, and, among patients not on invasive 159 mechanical ventilation at randomisation, invasive mechanical ventilation (including extra-160 corporal membrane oxygenation) or death. Prespecified subsidiary clinical outcomes 161 were use of non-invasive respiratory support, time to successful cessation of invasive 162 mechanical ventilation (defined as cessation of invasive mechanical ventilation within, 163 and survival to, 28 days), use of renal dialysis or haemofiltration, cause-specific mortality, 164 bleeding events, thrombotic events, major cardiac arrhythmias, thrombotic and bleeding 165 events, other infections and metabolic complications (including ketoacidosis). Information 166 on suspected serious adverse reactions was collected in an expedited fashion to comply 167 with regulatory requirements.

168

#### 169 Sample size and role of the independent Data Monitoring Committee

#### Empagliflozin for COVID-19

The intention for this comparison was to continue recruitment until sufficient primary outcomes had accrued to have 90% power to detect a proportional risk reduction of 20% at a two-sided significance level of 0.01.

The independent Data Monitoring Committee reviewed unblinded analyses of the study data and any other information considered relevant to the trial at intervals of around 2-3 months (depending on speed of enrolment) and was charged with determining if, in their view, the randomised comparisons in the study provided evidence on mortality that was strong enough (with a range of uncertainty around the results that was narrow enough) to affect national and global treatment strategies (appendix p 58).

On 3 March 2023, the Data Monitoring Committee recommended that the investigators
review the unblinded data from the empagliflozin comparison (appendix p 59).
Consequently, recruitment to the empagliflozin comparison was closed on 7 March 2023.

182

#### 183 Statistical Analysis

The primary analysis for all outcomes was by intention-to-treat comparing patients randomised to empagliflozin with patients randomised to usual care but for whom empagliflozin was both available and suitable as a treatment. For the primary outcome of 28-day mortality, the hazard ratio from an age- and respiratory status-adjusted Cox model was used to estimate the mortality rate ratio. We constructed Kaplan-Meier survival curves to display cumulative mortality over the 28-day period. We used the same Cox regression method to analyse time to hospital discharge and successful cessation of

#### Empagliflozin for COVID-19

191 invasive mechanical ventilation, with patients who died in hospital right-censored on day 192 29. Median time to discharge was derived from Kaplan-Meier estimates. For the pre-193 specified composite secondary outcome of progression to invasive mechanical ventilation 194 or death within 28 days (among those not receiving invasive mechanical ventilation at 195 randomisation), and the subsidiary clinical outcomes of receipt of ventilation and use of 196 haemodialysis or haemofiltration, the precise dates were not available and so a log-197 binomial regression model was used to estimate the risk ratio adjusted for age and 198 respiratory status.

Prespecified subgroup analyses were performed for the primary outcome using the statistical test of interaction (test for heterogeneity or trend), in accordance with the prespecified analysis plan, defined by the following characteristics at randomisation: age, sex, ethnicity, level of respiratory support, days since symptom onset, and use of corticosteroids (appendix p 139).

Estimates of rate and risk ratios are shown with 95% confidence intervals. All p-values are 2-sided and are shown without adjustment for multiple testing. The full database is held by the study team which collected the data from study sites and performed the analyses at the Nuffield Department of Population Health, University of Oxford (Oxford, UK).

Analyses were performed using SAS version 9.4 and R version 3.4. The trial is registered
with ISRCTN (50189673) and clinicaltrials.gov (NCT04381936).

#### 211 Role of the funding source

#### Empagliflozin for COVID-19

Neither the funders of the study nor Boehringer Ingelheim, which supplied empagliflozin for sites outside the UK, had any role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.

216

#### 217 **RESULTS**

218 Between 8 July 2021 and 6 March 2023, 4271 (74%) of 5740 patients enrolled into the 219 RECOVERY trial were eligible to be randomly allocated to empagliflozin (i.e. 220 empagliflozin was available in the hospital at the time and the attending clinician was of 221 the opinion that the patient had no known indication for or contraindication to 222 empagliflozin, figure 1). The characteristics of the 1469 patients enrolled into the 223 RECOVERY trial during this period but not included in the empagifilozin comparison are 224 shown in webtable 1. 2113 patients were randomly allocated to empagliflozin and 2158 225 were randomly allocated to usual care. The mean age of study participants in this 226 comparison was 61.5 years (SD 16.4) and the median time since symptom onset was 8 227 days (IQR 5 to 11 days). At randomisation, 3842 (90%) patients were receiving 228 corticosteroids, about one-quarter were receiving remdesivir and about one-quarter had 229 received tocilizumab (table 1).

The follow-up form was completed for 2089 (99%) patients in the empagliflozin group and 231 2138 (99%) patients in the usual care group. Among patients with a completed follow-up 232 form, 1889 (90%) allocated to empagliflozin received at least one dose and, of these, 233 1321 (70%) received it on most ( $\geq$ 90%) days of their admission (or until 28 days after

#### Empagliflozin for COVID-19

randomisation if not discharged sooner) (figure 1; webtable 2). By comparison, <1% of</li>
those allocated to usual care alone received any dose of empagliflozin. Use of other
treatments for COVID-19 was similar among patients allocated empagliflozin and among
those allocated usual care (webtable 2).

238 Primary and secondary outcome data are known for >99% of randomly assigned patients. 239 There was no evidence of a significant difference in the proportion of patients who met 240 the primary outcome of 28-day mortality between the two randomised groups (289 [14%] 241 patients in the empagliflozin group vs. 307 [14%] patients in the usual care group; hazard 242 ratio 0.96; 95% confidence interval [CI], 0.82-1.13; p=0.64; figure 2). We observed similar 243 results across all pre-specified sub-groups (figure 3), except among the small group of 244 patients not requiring oxygen at baseline or not receiving corticosteroids among whom 245 there were very few (about 20) events.

246 The median time to discharge from hospital alive was 8 days in both groups and there 247 was no evidence of a significant difference in the probability of being discharged alive 248 within 28 days (79 vs. 78%, rate ratio 1.03, 95% CI 0.96 to 1.10, p=0.44) (table 2). Among 249 those not on invasive mechanical ventilation at baseline, the number of patients 250 progressing to the pre-specified composite secondary outcome of invasive mechanical 251 ventilation or death was similar in both groups (16% vs. 17%, risk ratio 0.95, 95% CI 0.84 252 to 1.08, p=0.44). Similar results were seen in all pre-specified subgroups of patients 253 (webfigure 1, webfigure 2).

We found no evidence of significant differences in the prespecified subsidiary clinical outcomes of cause-specific mortality (webtable 3), use of ventilation or successful

#### Empagliflozin for COVID-19

256 cessation of invasive mechanical ventilation (table 2). We found no evidence of a 257 significant difference in the incidence of acute kidney injury (defined as an increase in the 258 pre-randomisation creatinine concentration of at least 50%), or need for renal dialysis or 259 haemofiltration (table 2, webtable 4). The incidence of new cardiac arrhythmias, bleeding 260 events, and non-coronavirus infections was also similar in the two groups (webtable 4). 261 There were fewer thrombotic events among patients allocated empagliflozin compared to placebo (2.5% vs. 3.9%, absolute difference -1.4% [-0.4 to -2.5]; webtable 4). The 262 263 incidence of metabolic complications were similar in the two groups, with reported 264 ketoacidosis in 5 vs. 2 patients. There were two reports of a serious adverse reaction 265 believed to be related to empagliflozin: both were ketosis without acidosis (including one 266 patient without diabetes) and resolved rapidly on cessation of the drug.

267

#### 268 **DISCUSSION**

In this large, randomised trial involving over 4000 patients from 7 countries and nearly 600 deaths, allocation to empagliflozin was not associated with reductions in mortality, duration of hospitalisation, or the risk of being ventilated or dying for those not on ventilation at baseline. These results were consistent across prespecified subgroups of age, sex, race and duration of symptoms prior to randomisation.

The benefits of immunomodulatory therapies in patients with moderate to severe COVID-19 demonstrates the importance of inflammation in this patient group and empagliflozin was proposed as a treatment for COVID-19 partly based on its anti-inflammatory activity as well as purported benefits on endothelial function and cellular energy metabolism. The

#### Empagliflozin for COVID-19

278 lack of evidence of benefit from empagliflozin in this large well-powered trial suggests that 279 these properties of empagliflozin are either insufficient to produce a meaningful reduction 280 in mortality risk or are not affecting the relevant pathways in moderate to severe COVID-281 19. There is weak evidence that there may be some benefit on 28-day mortality in patients 282 not receiving a corticosteroid or not requiring oxygen, which are largely the same patients. 283 However, this observation is based on a very small number of events, marginally 284 significant tests for heterogeneity or trend, and is not supported by either of the secondary 285 outcomes.

286 Only one other trial of an SGLT2i in COVID-19 has been reported to date. The DARE-19 287 trial recruited 1250 patients hospitalised (but not critically ill) with COVID-19 and with at 288 least one cardiometabolic risk factor (i.e. hypertension, type 2 diabetes mellitus, atherosclerotic cardiovascular disease, heart failure or chronic kidney disease).<sup>16</sup> There 289 290 was no significant effect of dapagliflozin on either of the two dual primary outcomes (new 291 or worsened organ function or death, and change in clinical status by day 30), although 292 there were numerically fewer poor outcomes in dapagliflozin group, including 41 deaths 293 compared to 54 in the placebo group. However, DARE-19 was not large enough to detect 294 plausibly moderate benefits of treatment. Meta-analysing the results on mortality from 295 DARE-19 and RECOVERY yields a summary relative risk of 0.93 (0.80-1.08). Trials of 296 SGLT2i in chronic disease setting have found consistent evidence of a reduction in acute kidney injury (AKI): a meta-analysis of 13 large placebo-controlled trials including over 297 298 2000 AKI events reported a reduction of nearly one-quarter (relative risk 0.77, 95% CI 299 0.70-0.84) in this outcome.<sup>1</sup> The RECOVERY trial did not find evidence of benefit (or

#### Empagliflozin for COVID-19

harm) of empagliflozin on the risk of developing AKI in the acute setting where AKI mayhave already begun prior to randomisation.

302 Strengths of this trial included that it was randomised, had a large sample size, broad 303 eligibility criteria, was international and more than 99% of patients were followed up for 304 the primary outcome. However, detailed information on laboratory markers of 305 inflammation and immune response was not collected, nor was information on 306 radiological or physiological outcomes. Although this randomised trial is open label (i.e., 307 participants and local hospital staff are aware of the assigned treatment), the outcomes 308 are unambiguous and were ascertained without bias through linkage to routine health 309 records in the large majority of patients.

310 The RECOVERY trial only studied patients who had been hospitalised with COVID-19 311 and, therefore, is not able to provide any evidence on the safety and efficacy of 312 empagliflozin used in other patient groups. Due to the recommendation that empagliflozin 313 be taken orally (and not via a gastric feeding tube), there were few patients recruited 314 requiring invasive mechanical ventilation. Nevertheless, the reassuring safety findings in 315 RECOVERY suggest that SGLT2i can be safely used in the acute setting and do not need 316 to be routinely discontinued if there is an appropriate indication. These results show that 317 the key risk of ketoacidosis can be safely mitigated with simple monitoring and advice to 318 managing physicians.

In summary, the results of this large, randomised trial do not support the use of empagliflozin as a treatment for adults hospitalised with COVID-19.

321

### Empagliflozin for COVID-19

### 322 Contributors

323 This manuscript was initially drafted by the RH, PWH and MJL, further developed by the 324 Writing Committee, and approved by all members of the trial steering committee. PWH 325 and MJL vouch for the data and analyses, and for the fidelity of this report to the study 326 protocol and data analysis plan. PWH, JKB, MB, MK, SNF, TJ, EJ, KJ, WSL, AMo, AMuk, 327 AMum, JN, KR, GT, MM, RH, and MJL designed the trial and study protocol. MM, MC, G 328 P-A, LP, RKJ, DG, JD, FH, AK, PT-T, JW, CG, PD, RS, the Data Linkage team at the 329 RECOVERY Coordinating Centre, and the Health Records and Local Clinical Centre staff 330 listed in the appendix collected the data. NS and JRE did the statistical analysis. All 331 authors contributed to data interpretation and critical review and revision of the 332 manuscript. PWH and MJL had access to the study data and had final responsibility for 333 the decision to submit for publication.

#### Empagliflozin for COVID-19

#### 335 Writing Committee (on behalf of the RECOVERY Collaborative Group):

Peter W Horby, Natalie Staplin, Leon Peto, Jonathan R Emberson, Mark Campbell, 336 337 Guilherme Pessoa-Amorim, Buddha Basnyat, Louise Thwaites, Rogier van Doorn, Raph 338 L Hamers, Jeremy Nel, John Amuasi, Roshan Kumar Jha, Dipansu Ghosh, Jonathan 339 Douse, Fergus Hamilton, Anthony Kerry, Pinky Thu-Ta, John Widdrington, Christopher A 340 Green, Purav Desai, Richard Stewart, Nguyen Thanh Phong, J Kenneth Baillie, Maya Buch, Saul N Faust, Thomas Jaki, Edmund Juszczak, Katie Jeffery, Marian Knight, Wei 341 342 Shen Lim, Alan Montgomery, Aparna Mukherjee, Andrew Mumford, Kathryn Rowan, Guy 343 Thwaites, Marion Mafham, Richard Haynes, Martin J Landray.

#### **Data Monitoring Committee**

- 345 Peter Sandercock, Janet Darbyshire, David DeMets, Robert Fowler, David Lalloo,
- 346 Mohammed Munavvar, Janet Wittes.

#### 347 **Declaration of interests**

The authors have no conflict of interest or financial relationships relevant to the submitted work to disclose. No form of payment was given to anyone to produce the manuscript. All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. The Nuffield Department of Population Health at the University of Oxford has a staff policy of not accepting honoraria or consultancy fees directly or indirectly from industry (see <u>https://www.ndph.ox.ac.uk/files/about/ndph-independence-</u> of-research-policy-jun-20.pdf).

#### 355 Data sharing

#### Empagliflozin for COVID-19

356 The protocol, consent form, statistical analysis plan, definition & derivation of clinical 357 characteristics & outcomes, training materials, regulatory documents, and other relevant 358 study materials are available online at www.recoverytrial.net. As described in the protocol, 359 the Trial Steering Committee will facilitate the use of the study data and approval will not 360 be unreasonably withheld. Deidentified participant data will be made available to bona 361 fide researchers registered with an appropriate institution within 3 months of publication. However, the Steering Committee will need to be satisfied that any proposed publication 362 363 is of high quality, honours the commitments made to the study participants in the consent 364 documentation and ethical approvals, and is compliant with relevant legal and regulatory 365 requirements (e.g. relating to data protection and privacy). The Steering Committee will 366 have the right to review and comment on any draft manuscripts prior to publication. Data 367 will be made available in line with the policy and procedures described at: https://www.ndph.ox.ac.uk/data-access. Those wishing to request access should 368 369 complete the form at 370 https://www.ndph.ox.ac.uk/files/about/data access enquiry form 13 6 2019.docx

and e-mailed to: <u>data.access@ndph.ox.ac.uk</u>

372

#### 373 Acknowledgements

Above all, we would like to thank the thousands of patients who participated in this trial. We would also like to thank the many doctors, nurses, pharmacists, other allied health professionals, and research administrators at NHS hospital organisations across the whole of the UK, supported by staff at the National Institute of Health Research (NIHR) Clinical Research Network, NHS DigiTrials, Public Health England, Department of Health

#### Empagliflozin for COVID-19

& Social Care, the Intensive Care National Audit & Research Centre, Public Health
Scotland, National Records Service of Scotland, the Secure Anonymised Information
Linkage (SAIL) at University of Swansea, and the NHS in England, Scotland, Wales and
Northern Ireland.

383 The RECOVERY trial is supported by grants to the University of Oxford from UK Research 384 and Innovation (UKRI) and NIHR (MC\_PC\_19056), the Wellcome Trust (Grant Ref: 385 222406/Z/20/Z) through the COVID-19 Therapeutics Accelerator, and by core funding 386 provided by the NIHR Oxford Biomedical Research Centre, the Wellcome Trust, the Bill 387 and Melinda Gates Foundation, the Foreign, Commonwealth and Development Office, 388 Health Data Research UK, the Medical Research Council Population Health Research 389 Unit, the NIHR Health Protection Unit in Emerging and Zoonotic Infections, and NIHR 390 Clinical Trials Unit Support Funding. TJ is supported by a grant from UK Medical 391 Research Council (MC UU 0002/14). WSL is supported by core funding provided by 392 NIHR Nottingham Biomedical Research Centre. Boehringer-Ingelheim supplied 393 empagliflozin free of charge for use in this trial in countries outside the UK. Boehringer 394 Ingelheim was given the opportunity to review the manuscript for medical and scientific 395 consistency as it relates to Boehringer Ingelheim substances, as well as intellectual 396 property considerations.

397 The views expressed in this publication are those of the authors and not necessarily those 398 of the NHS, the NIHR, or the UK Department of Health and Social Care.

#### **Conflicts of interest**

# Empagliflozin for COVID-19

RH and MJL are named on grants to the University of Oxford from Boehringer-Ingelheim for other research projects. No form of payment was given to anyone to produce the manuscript. All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. The Nuffield Department of Population Health at the University of Oxford has a staff policy of not accepting honoraria or consultancy fees directly or indirectly from industry (see <a href="https://www.ndph.ox.ac.uk/files/about/ndph-independence-of-research-policy-jun-20.pdf">https://www.ndph.ox.ac.uk/files/about/ndphindependence-of-research-policy-jun-20.pdf</a>).

# Empagliflozin for COVID-19

# 408 **References**

Nuffield Department of Population Health Renal Studies Group and the SGLT2
 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium. Impact of diabetes on the
 effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative
 meta-analysis of large placebo-controlled trials. *Lancet*. Nov 19 2022;400(10365):1788 1801. doi:10.1016/S0140-6736(22)02074-8

- Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019
  novel coronavirus in Wuhan, China. *Lancet*. Feb 15 2020;395(10223):497-506.
  doi:10.1016/S0140-6736(20)30183-5
- Wang JH, Chen RD, Yang HK, et al. Inflammation-associated factors for
  predicting in-hospital mortality in patients with COVID-19. *J Med Virol*. May
  2021;93(5):2908-2917. doi:10.1002/jmv.26771
- 4. W. H. O. Rapid Evidence Appraisal for COVID-19 Therapies Working Group,
  Sterne JAC, Murthy S, et al. Association Between Administration of Systemic
  Corticosteroids and Mortality Among Critically III Patients With COVID-19: A Metaapplyzing Jame Oct 6 2020;224(12):1220–1241, doi:10.1001/jamp.2020.17022
- 423 analysis. *Jama*. Oct 6 2020;324(13):1330-1341. doi:10.1001/jama.2020.17023
- 424 5. Group WHOREAfC-TW, Shankar-Hari M, Vale CL, et al. Association Between
  425 Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for
  426 COVID-19: A Meta-analysis. *Jama*. Aug 10 2021;326(6):499-518.
  427 doi:10.1001/jama.2021.11330
- 6. Group RC. Baricitinib in patients admitted to hospital with COVID-19
  (RECOVERY): a randomised, controlled, open-label, platform trial and updated metaanalysis. *Lancet*. Jul 30 2022;400(10349):359-368. doi:10.1016/S0140-6736(22)011096
- 432 7. Maayah ZH, Ferdaoussi M, Takahara S, Soni S, Dyck JRB. Empagliflozin
  433 suppresses inflammation and protects against acute septic renal injury.
  434 *Inflammopharmacology*. Feb 2021;29(1):269-279. doi:10.1007/s10787-020-00732-4
- 8. Bonnet F, Scheen AJ. Effects of SGLT2 inhibitors on systemic and tissue lowgrade inflammation: The potential contribution to diabetes complications and
  cardiovascular disease. *Diabetes & metabolism*. Dec 2018;44(6):457-464.
  doi:10.1016/j.diabet.2018.09.005
- 439 9. Rodrigues TS, Keyla SG, Ishimoto AY, et al. Inflammasome activation in COVID440 19 patients. *medRxiv*. 2020;doi:<u>https://doi.org/10.1101/2020.08.05.20168872</u>
- 441 10. Kim SR, Lee SG, Kim SH, et al. SGLT2 inhibition modulates NLRP3
- inflammasome activity via ketones and insulin in diabetes with cardiovascular disease.
- 443 Nat Commun. May 1 2020;11(1):2127. doi:10.1038/s41467-020-15983-6

# Empagliflozin for COVID-19

Li H-L, Tse Y-K, Chandramouli C, et al. Sodium-Glucose Cotransporter 2
Inhibitors and the Risk of Pneumonia and Septic Shock. *The Journal of Clinical Endocrinology & Metabolism*. 2022;107(12):3442-3451. doi:10.1210/clinem/dgac558

12. Daniele G, Xiong J, Solis-Herrera C, et al. Dapagliflozin Enhances Fat Oxidation
and Ketone Production in Patients With Type 2 Diabetes. *Diabetes care*. Nov
2016;39(11):2036-2041. doi:10.2337/dc15-2688

Icard P, Lincet H, Wu Z, et al. The key role of Warburg effect in SARS-CoV-2
replication and associated inflammatory response. *Biochimie*. Jan 2021;180:169-177.
doi:10.1016/j.biochi.2020.11.010

453 14. Codo AC, Davanzo GG, Monteiro LB, et al. Elevated Glucose Levels Favor
454 SARS-CoV-2 Infection and Monocyte Response through a HIF-1α/Glycolysis455 Dependent Axis. *Cell Metab.* Sep 1 2020;32(3):437-446.e5.

456 doi:10.1016/j.cmet.2020.07.007

457 15. Solini A, Giannini L, Seghieri M, et al. Dapagliflozin acutely improves endothelial
458 dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients:
459 a pilot study. *Cardiovasc Diabetol*. Oct 23 2017;16(1):138. doi:10.1186/s12933-017460 0621-8

461 16. Kosiborod MN, Esterline R, Furtado RHM, et al. Dapagliflozin in patients with
462 cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised,
463 double-blind, placebo-controlled, phase 3 trial. *Lancet Diabetes Endocrinol.* Sep
464 2021;9(9):586-594. doi:10.1016/S2213-8587(21)00180-7

465 17. RECOVERY Collaborative Group, Horby P, Lim WS, et al. Dexamethasone in
466 Hospitalized Patients with Covid-19. *N Engl J Med.* Feb 25 2021;384(8):693-704.
467 doi:10.1056/NEJMoa2021436

18. RECOVERY Collaborative Group, Horby P, Mafham M, et al. Effect of
Hydroxychloroquine in Hospitalized Patients with Covid-19. *N Engl J Med.* Nov 19
2020;383(21):2030-2040. doi:10.1056/NEJMoa2022926

471 19. RECOVERY Collaborative Group, Horby PW, Mafham M, et al. Lopinavir472 ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised,
473 controlled, open-label, platform trial. *Lancet*. Oct 5 2020;396(10259):1345-52.
474 doi:10.1016/S0140-6736(20)32013-4

475 20. RECOVERY Collaborative Group. Azithromycin in patients admitted to hospital
476 with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
477 Lancet. Feb 13 2021;397(10274):605-612. doi:10.1016/S0140-6736(21)00149-5

478 21. RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital
479 with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
480 Lancet. May 1 2021;397(10285):1637-1645. doi:10.1016/S0140-6736(21)00676-0

# Empagliflozin for COVID-19

481 22. RECOVERY Collaborative Group, Horby PW, Estcourt L, et al. Convalescent

482 plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised,

483 controlled, open-label, platform trial. *medRxiv*. 2021:2021.03.09.21252736.

484 doi:10.1101/2021.03.09.21252736

485 23. Group RC. Colchicine in patients admitted to hospital with COVID-19

486 (RECOVERY): a randomised, controlled, open-label, platform trial. *Lancet Respir Med.* 487 Dec 2021;9(12):1419-1426. doi:10.1016/S2213-2600(21)00435-5

488 24. Group RC. Aspirin in patients admitted to hospital with COVID-19 (RECOVERY):
489 a randomised, controlled, open-label, platform trial. *Lancet.* Jan 8 2022;399(10320):143490 151. doi:10.1016/S0140-6736(21)01825-0

491 25. Group RC. Casirivimab and imdevimab in patients admitted to hospital with

492 COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. *Lancet.* 493 Feb 12 2022;399(10325):665-676. doi:10.1016/S0140-6736(22)00163-5

494 26. RECOVERY Collaborative Group. Higher dose corticosteroids in hospitalised

495 COVID-19 patients with hypoxia but not requiring ventilatory support (RECOVERY): a

496 randomised, controlled, open-label, platform trial. MedRxiv.

497 2023;doi:https://doi.org/10.1101/2022.12.16.22283578

498

## Empagliflozin for COVID-19

# 500 **Table 1: Baseline characteristics**

	Treatment	allocation
	Empagliflozin (n=2113)	Usual care (n=2158)
Age, years	61.1 (16.3)	61.8 (16.4)
<70	1412 (67%)	1393 (65%)
≥70 to <80	434 (21%)	479 (22%)
≥80	267 (13%)	286 (13%)
≥oo	207 (1378)	200 (1370)
Male	1326 (63%)	1339 (62%)
Female*	787 (37%)	819 (38%)
Country	101 (3176)	019 (30 %)
Ghana	2(-0.5%)	2 ( -0 59/ )
India	2 (<0.5%)	2 (<0.5%)
Indonesia	24 (1%)	19 (1%)
	68 (3%) 120 (7%)	68 (3%)
Nepal South Africa	139 (7%) 10 (~0 5%)	119 (6%) 14 (1%)
Vietnam	10 (<0.5%)	14 (1%) 53 (2%)
UK	40 (2%)	53 (2%)
Race	1830 (87%)	1883 (87%)
White	1557 (749/)	1607 (749/)
	1557 (74%) 361 (17%)	1607 (74%)
Black, Asian, and minority ethnic Unknown		330 (15%)
	195 (9%)	221 (10%)
Number of days since symptom onset Number of days since hospitalisation	8 (5-11) 2 (1-3)	8 (5-12) 2 (1-3)
	2 (1-3)	2 (1-3)
Respiratory support received None	255 (12%)	260 (12%)
	255 (12%)	260 (12%)
Simple oxygen Non invasive ventilation	1317 (62%) 512 (24%)	1383 (64%) 500 (23%)
Invasive mechanical ventilation	29 (1%)	15 (1%)
	29 (1%)	15 (1%)
Biochemistry	92 (20 149)	05 (20 151)
C-reactive protein, mg/L	83 (39-148)	85 (38-151)
Creatinine, umol/L Previous diseases	75 (62-94)	78 (63-96)
Diabetes	222 (169/)	256 (169/)
Heart disease	333 (16%)	356 (16%)
Chronic lung disease	471 (22%) 533 (25%)	455 (21%) 508 (24%)
Tuberculosis		
HIV	9 (<0.5%) 21 (1%)	7 (<0.5%) 13 (1%)
Severe liver disease†	21 (1%) 20 (1%)	21 (1%)
Severe kidney impairment‡	20 (1%) 66 (3%)	80 (4%)
Any of the above	1014 (48%)	1039 (48%)
SARS-CoV-2 PCR test result	1014 (40%)	1039 (40%)
Positive	2016 (07%)	2007 (070/)
	2046 (97%)	2097 (97%)
Negative	12 (1%) 55 (2%)	10 (<0.5%)
	55 (3%) 1412 (67%)	51 (2%)
Received a COVID-19 vaccine	1412 (67%)	1453 (67%)
Use of other treatments	1010 (00%)	1000 (000/)
Corticosteroids	1910 (90%)	1932 (90%)
Remdesivir Tocilizumab	541 (26%)	547 (25%)
	504 (24%)	491 (23%)
Plan to use tocilizumab within the next 24 hours	208 (10%)	240 (11%)

# Empagliflozin for COVID-19

	Treatment allocation	
	Empagliflozin (n=2113)	Usual care (n=2158)
Other randomly assigned treatments		
Baricitinib	554 (26%)	591 (27%)
High dose steroids	160 (8%)	161 (7%)
Sotrovimab	185 (9%)	194 (9%)
Molnupiravir	143 (7%)	133 (6%)
Nirmatrelvir-ritonavir	19 (1%)	28 (1%)

Results are count (%), mean ± standard deviation, or median (inter-quartile range). \*Includes 0 pregnant women. †Defined as requiring ongoing specialist care. ‡Defined as estimated glomerular filtration rate <30 mL/min/1.73m<sup>2</sup>

501

# Empagliflozin for COVID-19

# 503 Table 2: Effect of allocation to empagliflozin on key study outcomes

	Treatment			
	Empagliflozin (n=2113)	Usual care (n=2158)	RR (95% CI)	p value
Primary outcome:				
28-day mortality	289 (14%)	307 (14%)	0.96 (0.82-1.13)	0.64
Secondary outcomes:				
Median time to being discharged alive, days	8 (5 to 19)	8 (5 to 20)		
Discharged from hospital within 28 days	1678 (79%)	1677 (78%)	1.03 (0.96-1.10)	0.44
Receipt of invasive mechanical ventilation or death*	338/2084 (16%)	371/2143 (17%)	0.95 (0.84-1.08)	0.44
Invasive mechanical ventilation	130/2084 (6%)	133/2143 (6%)	0.97 (0.77-1.21)	0.77
Death	274/2084 (13%)	302/2143 (14%)	0.96 (0.84-1.11)	0.59
Subsidiary clinical outcomes				
Receipt of ventilation†	245/1567 (16%)	259/1641 (16%)	1.00 (0.85-1.17)	0.97
Non-invasive ventilation	237/1572 (15%)	252/1643 (15%)	0.99 (0.84-1.16)	0.90
Invasive mechanical ventilation	51/1567 (3%)	49/1641 (3%)	1.09 (0.74-1.60)	0.66
Successful cessation of invasive mechanical ventilation	10/29 (35%)	6/15 (40%)	0.67 (0.24-1.85)	0.44
Renal replacement therapy§	45/2103 (2%)	44/2146 (2%)	0.96 (0.64-1.45)	0.86

RR=Rate Ratio for the outcomes of 28-day mortality and hospital discharge, and risk ratio for the outcome of receipt of invasive mechanical ventilation or death (and its subcomponents). Cl=confidence interval. \*Analyses exclude those on invasive mechanical ventilation at randomization. †Analyses exclude those on any form of ventilation at randomisation. ‡Analyses restricted to those on invasive mechanical ventilation at randomisation. \$Analyses exclude those on invasive mechanical ventilation at randomisation. \$Analyses exclude those on invasive mechanical ventilation at randomisation. \$Analyses exclude those on haemodialysis or haemofiltration at randomisation.

504

#### Empagliflozin for COVID-19

#### 506 Figures


#### 507 **Figure 1: Trial profile**

- 508 ITT=intention to treat. \* Number recruited overall during period that adult participants
- 509 could be recruited into empagliflozin comparison. Of the 4271 randomised to
- 510 empagliflozin vs usual care, 1145 were additionally randomised to baricitinib vs usual
- 511 care (554 [26%] of the empagliflozin group vs 591 [27%] of the usual care group); 321
- 512 were additionally randomised to higher-dose corticosteroids vs usual care (160 [8%] of
- 513 the empagliflozin group vs 161 [7%] of the usual care group); 379 were additionally
- randomised to sotrovimab vs usual care (185 [9%] of the empagliflozin group vs 194
- 515 [9%] of the usual care group); 276 were additionally randomised to molnupiravir vs
- usual care (143 [7%] of the empagliflozin group vs 133 [6%] of the usual care group);
- and 47 patients were additionally randomised to nirmatrelvir-ritonavir vs usual care (19
- 518 [1%] of the empagliflozin group vs 28 [1%] of the usual care group).
- 519 Figure 2: Effect of allocation to empagliflozin on 28-day mortality


#### 520 Figure 3: Effect of allocation to empagliflozin on 28-day mortality by baseline

#### 521 characteristics

522 Subgroup-specific rate ratio estimates are represented by squares (with areas of the 523 squares proportional to the amount of statistical information) and the lines through them 524 correspond to the 95% CIs. The ethnicity, days since onset and use of corticosteroids 525 subgroups exclude those with missing data, but these patients are included in the overall 526 summary diamond.



ITT=intention to treat. \*Number recruited overall during period that adult participants could be recruited into empagliflozin comparison.



# Figure 3: Effects of allocation to empagliflozin on 28- day mortality by baseline characteristics

	Empagliflozin	Usual care		RR (95% CI)
Age, years ( $\chi_{1}^{2}$ =0.1; p=0.8	1)			
<70	123/1412 (9%)	115/1393 (8%)	<b>_</b>	1.01 (0.78- 1.30)
≥70 <80	92/434 (21%)	113/479 (24%)	<b>-</b>	0.90 (0.68- 1.18)
≥80	74/267 (28%)	79/286 (28%)		0.98 (0.71- 1.34)
Sex (χ <sub>1</sub> <sup>2</sup> =0.0; p=0.98)				
Men	189/1326 (14%)	205/1339 (15%)		0.96 (0.79- 1.18)
Women	100/781 (13%)	102/817 (13%)		0.96 (0.73- 1.27)
Race (χ <sub>1</sub> <sup>2</sup> =1.0; p=0.33)				
White	240/1557 (15%)	257/1607 (16%)	<b>_</b>	0.98 (0.82- 1.17)
BAME	30/361 (8%)	32/330 (10%)	<	0.75 (0.46- 1.24)
Days since symptom onse	et (χ <sub>1</sub> <sup>2</sup> =0.0; p=0.91)			
≤7	146/1168 (12.5%)	162/1246 (13.0%)		0.96 (0.77- 1.21)
>7	143/945 (15.1%)	145/912 (15.9%)		0.95 (0.75- 1.19)
Respiratory support at rai	ndomization ( $\chi_1^2$ =4.7;	p=0.03)		
None	4/255 (2%)	18/260 (7%)	←──	0.24 (0.08- 0.70)
Simple oxygen	142/1317 (11%)	162/1383 (12%)		0.92 (0.74- 1.16)
Non invasive ventilation	128/512 (25%)	122/500 (24%)		1.08 (0.84- 1.39)
Invasive mechanical ventila	tion 15/29 (52%)	5/15 (33%)		> 1.68 (0.61-4.62)
Use of corticosteroids ( $\chi_1^2$	=6.0; p=0.01)			
Yes	284/1910 (15%)	287/1932 (15%)	<b></b>	1.01 (0.86- 1.19)
No	5/197 (3%)	19/218 (9%)	←──	0.29 (0.11- 0.78)
All participants	289/2113 (14%)	307/2158 (14%)		0.96 (0.82- 1.13) p=0.64
			0.5 0.75 1 1.5	2
			Empagliflozin Empagliflozi better worse	n